Boosting CRISPR/Cas12a intrinsic RNA detection capability through pseudo hybrid DNA–RNA substrate design
Nucleic Acids Research · 06.06.2025 · 53 (11)
DOI: 10.1093/nar/gkaf510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 11.06.2025. Verfasst von Jie Qiao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pilot Base of Food Microbial Resources Utilization of Hubei Province, School of Life Science and Technology, Wuhan Polytechnic University, Hubei 4300…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, CRISPR-Associated Proteins, DNA, RNA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Science and Technology Innovation Talent Plan of Hubei Province, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
The CRISPR/Cas12a [clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated protein 12a] system is known for its intrinsic RNA-guided trans-cleavage activity; however, its RNA detection sensitivity is limited, with conventional methods typically achieving detection limits in the nanomolar range. Here, we report the development of a “pseudo hybrid DNA–RNA” (PHD) assay that significantly enhances the RNA detection capability of Cas12a. The PHD assay achieves a striking detection limit of 7.7 pM using single CRISPR RNA (crRNA) and 33.8 fM using pooled crRNAs. Importantly, this assay exhibits ultra-high specificity, capable of distinguishing mutated RNA target sequences at the protospacer adjacent motif (PAM)-distal region. It can also detect ultrashort RNA sequences as short as 6–8 nt and long RNAs with complex secondary structures. Additionally, the PHD assay enables PAM-free attomolar-level DNA detection. We further demonstrate the practical utility of the PHD assay by successfully detecting miR-155 biomarkers and human pappilloma virus 16 DNA in clinical samples. We anticipate that the design principles established in this study can be extended to other CRISPR/Cas enzymes, thereby accelerating the development of powerful nucleic acid testing tools for various applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pilot Base of Food Microbial Resources Utilization of Hubei Province, School of Life Science and Technology, Wuhan Polytechnic University, Hubei 430023, China.
- State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Hubei 430042, China.
- Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450001, China.
- BravoVax Co., Ltd, Wuhan, Hubei 430075, China.
ORCID-Profile: Yi Liu
Förderung
- National Key Research and Development Program of China
- Science and Technology Innovation Talent Plan of Hubei Province
- Natural Science Foundation of Hubei Province
Zitieren
APA
Qiao, J., Zhang, J., Jiang, Q., Jin, S., He, R., Qiao, B., & Liu, Y. (2025). Boosting CRISPR/Cas12a intrinsic RNA detection capability through pseudo hybrid DNA–RNA substrate design. Nucleic Acids Research, 53(11). https://doi.org/10.1093/nar/gkaf510
Vancouver
Qiao J, Zhang J, Jiang Q, Jin S, He R, Qiao B, et al. Boosting CRISPR/Cas12a intrinsic RNA detection capability through pseudo hybrid DNA–RNA substrate design. Nucleic Acids Research. 2025;53(11). doi:10.1093/nar/gkaf510
BibTeX
@article{Qiao2025,
author = {Qiao, Jie and Zhang, Junqi and Jiang, Qingyuan and Jin, Shuqi and He, Ruyi and Qiao, Bin and Liu, Yi},
title = {Boosting CRISPR/Cas12a intrinsic RNA detection capability through pseudo hybrid DNA–RNA substrate design},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {11},
doi = {10.1093/nar/gkaf510}
}
EUVIMED